Former iron ore miner West African Minerals Corp. said its shareholders approved changing the company's name to OKYO Pharma Ltd.
The company will also delist its shares from the London Stock Exchange's AIM market and will instead transition to the bourse's main market.
OKYO Pharma is looking to acquire assets in the life sciences and biotechnology industry. The company said it is considering a deal with On Target Therapeutics LLC for the rights to a patent for an ocular inflammation, dry eye disease and ocular neuropathic pain treatment.
